Evidence map›Paper›PMID 40788411›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Efficacy of intensive antiemetic therapy including olanzapine in multiple myeloma patients treated with high-dose melphalan with autologous stem cell transplantation.

Junpei Kato, Masashi Uchida, Masayuki Ishikawa, Shinya Tatsuta, Takeshi Yoshimi, Kota Ishida, Osamu Hosoya, Nobuhiro Tsukada, Tadao Ishida, Yuki Shiko and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Junpei KatoDepartment of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
Masashi UchidaDivision of Pharmacy, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan. masac-u@chiba-u.jp.
Masayuki IshikawaGraduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Shinya TatsutaDepartment of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
Takeshi YoshimiDepartment of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
Kota IshidaDepartment of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
Osamu HosoyaDepartment of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
Nobuhiro TsukadaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Tadao IshidaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Yuki ShikoDepartment of Biostatistics, Graduate School of Medicine, Saitama Medical University, Saitama, Japan.
Yohei KawasakiDepartment of Biostatistics, Graduate School of Medicine, Saitama Medical University, Saitama, Japan.
Shingo YamazakiGraduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Itsuko IshiiGraduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeConditioning with high-dose melphalan (MEL) followed by autologous stem cell transplantation (ASCT) is the standard treatment for multiple myeloma (MM). The optimal regimen to prevent chemotherapy-induced nausea and vomiting (CINV) is unclear. We aimed to retrospectively evaluate the antiemetic effect and safety of a four-drug intensive regimen including olanzapine (OLA) on CINV in MM patients receiving MEL/ASCT.

methodsMEL (200 mg/m

resultsThere were no significant differences in baseline characteristics between the OLA (n = 68) and standard (n = 54) groups. The complete response rate in the IAR group was significantly higher in the delayed phase (52.9% vs. 31.4%, p < 0.05). Multivariate analysis revealed that the IAR was associated with the complete response rate (OR, 2.34; 95% CI, 1.09-5.00; p = 0.028). The incidence of nausea (grade 3) in the delayed phase was lower in the IAR group (44.1% vs. 75.9%, p < 0.001).

conclusionThe four-drug intensive regimen including OLA may improve the antiemetic effect on delayed CINV while also ensuring safety in MM patients undergoing MEL/ASCT.

Indexed as

AntiemeticsBenzodiazepinesMelphalanMultiple MyelomaNauseaStem Cell TransplantationVomitingAdultAgedAntineoplastic Agents, AlkylatingAprepitantDexamethasoneDrug Therapy, CombinationFemaleHumansIsoquinolinesAntiemeticsAntineoplastic Agents, AlkylatingAprepitantBenzodiazepinesDexamethasoneIsoquinolinesMelphalanMorpholinesOlanzapinePalonosetronQuinuclidinesAutologous stem cell transplantation multiple myelomaChemotherapy-induced nausea and vomitingHigh-dose melphalanOlanzapine

Identifiers

PMID40788411
PMCPMC12339614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.